Benchling has launched its inaugural 2023 State of Tech in Biopharma report, which has make clear the obstacles that biopharma encounter when striving to totally implement and embrace these applied sciences.
The report surveyed 300 R&D and IT consultants from biopharma corporations giant and small to do a first-ever investigation into biopharma’s use of an enabling tech stack — consisting of robotics and automation, linked devices, R&D information platforms, cloud-based scientific purposes, and AI and ML.
The report finds that the biopharma business is extensively adopting enabling tech, with R&D information platforms essentially the most extensively adopted (at 70%), adopted by robotics and automation platforms (63%), AI and ML (59%). Nevertheless, the adoption of SaaS software program is lagging, with solely 18% of respondents utilizing it for almost all of their R&D and IT work.
This excessive tech adoption has additionally corresponded with a fancy tech setting in labs — with 53% of scientists utilizing 5+ distinctive scientific software program purposes every day, and 40% of IT at giant corporations supporting greater than 20 purposes. 84% are utilizing some custom-built software program, indicating a holdover of legacy techniques. As well as, 41% of scientists discover collaborating with and throughout groups a problem, and 38% are needing to collaborate with 20 or extra individuals of their day-to-day work.
With such complexity, FAIR information rules are nonetheless out of attain – with restricted progress in reaching organisation-wide information interoperability (I) at 28%, and information reusability (R) at 30%.
The report additionally reveals that the 2 largest boundaries to adopting enabling tech and having the ability to work with it successfully is a scarcity of expert expertise, and science-specific options. This exhibits a transparent name to motion for the business to spend money on attracting the appropriate expertise to work with rising applied sciences, and those that have a robust need to construct new, fit-for-purpose scientific software program that may delight scientists and unlock IT groups.
Benchling’s analysis reveals corporations additionally have to take a logical step of fostering stronger alignment between their R&D and IT organisations — together with rationalising divergent tech priorities and having an trustworthy dialogue on the true boundaries to adoption, equivalent to organisational tradition and alter administration. Within the coming years, the significance of scientific information and AI will solely develop, placing further strain on biopharma to desert legacy tech and construct a stronger digital basis.
Bob Burke, EMEA GM at Benchling, stated: “We’re witnessing a outstanding period in biopharma, the place groundbreaking therapies and technological improvements are reshaping illness prevention and therapy. Enabling tech helps corporations carry the facility of automation, cloud, and AI to bear on issues of velocity, high quality, success, and scalability in biopharma.
“Our report highlights the hurdles that have to be surmounted to speed up scientific progress. Within the years forward, scientific information and AI will acquire even higher significance, intensifying the necessity for biopharma to shed legacy tech and fortify its digital basis. Firms able to attracting prime expertise, fostering alignment between R&D and IT, and swiftly adopting new applied sciences, the appropriate applied sciences that are constructed for this new period of biology, are poised to turn out to be essentially the most influential gamers in biopharma, driving success for generations to come back”.
“To propel the UK towards its science superpower imaginative and prescient, it’s crucial that we appeal to extra technical expertise to the life sciences business, upskill and prepare present workers, and prioritise user-friendly and built-for-biology SaaS and tech instruments. Expertise is right here and the roots are right here however we have to do a greater job of connecting the dots between tech innovation and the chance in life sciences.”
Benchling is the pioneer of the R&D Cloud, software program that unlocks the facility of biotechnology. Greater than 200,000 scientists at over 1,200 corporations and seven,500 educational and analysis establishments globally have adopted the Benchling R&D Cloud to make breakthrough discoveries and convey the subsequent era of medicines, meals, and supplies to market sooner. The Benchling R&D Cloud helps these organisations modernise their scientific processes and speed up collaboration to allow them to convert the complexity of biology into world-changing outcomes. For extra, please go to Benchling.com.
Methodology The report relies on an internet survey carried out from July thirteenth to August 1st, with 300 respondents from the prescribed drugs and biotechnology business. Respondents included 59% from R&D and 41% from IT, with 55% from giant corporations and 45% from small corporations.
Wish to study extra about cybersecurity and the cloud from business leaders? Take a look at Cyber Safety & Cloud Expo going down in Amsterdam, California, and London. Discover different upcoming enterprise expertise occasions and webinars powered by TechForge right here.